Submit your articles to the African Journal of Biomedical Research, active in Scopus Q3 and Clarivate Web of Science Zoological Records. Click here to submit your manuscript.
Volume 7 (2020) | Issue 10
Volume 11 (2024) | Issue 5
Volume 11 (2024) | Issue 5
Volume 11 (2024) | Issue 5
Volume 11 (2024) | Issue 5
Abstract: The purpose of the research: to determine the clinical effectiveness of complex therapy with cholinealfoscerate drugs as a supplement to standard therapy in patients in the acute period of ischemic stroke of hemisphere localization. Materials and methods: Sixty patients with acute cerebral stroke were examined, with an average age of 56+_ to 4.38. The main methods of the study were the collection of complaints and history, analysis of medical records, assessment of somatic and neurological status, paraclinical research methods (MRI), study of cognitive functions. The examination of patients was carried out during the acute period of stroke and repeated after 3 months. The results have been processed statistically. Results.The study revealed that the use of drugs of the group cholinealphoszerate in the acute phase of stroke and in the next 2 months has a beneficial effect not only on the restoration of motor and sensitive neurological deficits, improved cardiac activity, but also reduces the incidence of early post-stroke dementia (high confidence) and reduces the severity of clinical manifestations of lung and moderate cognitive disorders. Conclusions. For the comprehensive correction of the manifestations of ACCD and the prevention of post-stroke dementia, as well as reducing the progression of cognitive disorders, stroke patients should recommend the use of drugs chodinoalfoscerat (Cerepro) (in a dose of 2000mg/day intravenous drip for 5 days, then 1000mg/day intravenous5 days, then 1 restorative tablet 2 times a day (800mg/day) - 2 months) from the first days of stroke and in the early period.